Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifaximin Novel Formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 - Low Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Mid Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - High Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Max Dose | EXPERIMENTAL | Rifaximin Formulation 1 Capsules |
| Formulation 1 Capsules - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 1 Capsules |
| Formulation 2 - Low Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2- Mid Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - High Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - Max Dose | EXPERIMENTAL | Rifaximin Formulation 2 Capsules |
| Formulation 2 - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 2 Capsules |
| Formulation 3 - Low dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Mid dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - High dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Max dose | EXPERIMENTAL | Rifaximin Formulation 3 Capsules |
| Formulation 3 - Placebo | PLACEBO_COMPARATOR | Placebo Formulation 3 Capsules |
| Name | Type | Description |
|---|---|---|
| Rifaximin Novel Formulation | DRUG | Rifaximin Novel Formulation |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * The participant has the ability and willingness to sign a written informed consent, is either male or female aged between 18 and 65 years, inclusive, at the time of informed consent, is in good general health, and has a body mass index (BMI) at least 18 kg/m2 and at most 34 kg...
Rifaximin Novel Formulation is an investigational small molecule being studied in healthy volunteers. It is a novel formulation of rifaximin, an antibiotic, and is currently in Phase 1 clinical development. The drug is being evaluated for safety and pharmacokinetics, not for a specific disease indication.
Rifaximin Novel Formulation is being developed by Bausch Health Companies Inc. (NYSE: BHC). The company is conducting Phase 1 clinical trials to evaluate the safety and pharmacokinetics of this novel formulation of rifaximin in healthy volunteers.
Rifaximin Novel Formulation is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and pharmacokinetic profile.
Rifaximin Novel Formulation has one completed Phase 1 clinical trial, NCT04529811, titled 'Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers.' The trial enrolled 124 participants in New Zealand and was placebo-controlled, though not double-blinded.
Rifaximin Novel Formulation is a novel formulation of rifaximin, an antibiotic. While it contains the same active ingredient, the formulation is modified, which may affect its pharmacokinetics. The drug is being studied in healthy volunteers to evaluate these differences.